A commentary on "Breast-conserving surgery is associated with a lower incidence of suicide among females with breast cancer in the United States: a population-based retrospective cohort study" - Brice ño-Morales C, Briceño-Morales X.
[Abstract unavailable]
Language: en... (Source: SafetyLit)
Source: SafetyLit - April 25, 2024 Category: International Medicine & Public Health Tags: Research Methods, Surveillance and Codes, Models Source Type: news
FDA Greenlights Imaging Agent to Detect Residual Cancer After Lumpectomy
(MedPage Today) -- The FDA approved pegulicianine (LumiSight) as an optical imaging agent for detecting residual cancer after breast-conserving surgery (BCS).
The approval stipulates use of pegulicianine with the Lumicell Direct Visualization... (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - April 18, 2024 Category: OBGYN Source Type: news
Is semiannual mammo after breast conserving surgery necessary?
Annual mammography with a clinical exam -- rather than semiannual -- is “likely sufficient” for women who have undergone breast-conserving surgery and were treated with neoadjuvant therapy, a study published March 2 in Surgical Oncology Insight has found. Researchers led by Ton Wang, MD, from Cedars-Sinai Medical Center in Los Angeles found insufficient evidence supporting the use of semiannual mammography in these women, with less than 2% of women developing locoregional recurrence on routine surveillance. “Semiannual mammography is associated with unnecessary benign biopsies, which may increase health care costs ...
Source: AuntMinnie.com Headlines - March 8, 2024 Category: Radiology Authors: Amerigo Allegretto Tags: Subspecialties Womens Imaging Breast Imaging Source Type: news
MIDAC gives the nod to Lumicell ’s Lumisight
The Medical Imaging Drugs Advisory Committee (MIDAC) has voted in support of the benefit-risk profile of Lumisight.
During a March 5 meeting, MIDAC members voted 16 to 2 in favor of the company’s recent new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for its Lumisight optical imaging agent for breast cancer and a premarket approval application (PMA) for the company's direct visualization system.
The company’s combined product is an intracavity, fluorescence-guided surgical imaging tool used to detect residual cancer in real-time during lumpectomy surgery, also known as breast-conserving surg...
Source: AuntMinnie.com Headlines - March 7, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Breast Imaging Source Type: news
Lumicell Announces FDA Advisory Committee ’s Positive Recommendation on the Benefit-Risk Profile of Lumisight in the Detection of Cancerous Tissue During Breast Conserving Surgery
NEWTON, Massachusetts March 6, 2024– Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies for cancer, today announced the Medical Imaging Drugs Advisory Committee (MIDAC) of the U.S Food and... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - March 6, 2024 Category: Drugs & Pharmacology Source Type: news
CEM image quality unaffected by iron particles from tracers
Low-dose iron oxide tracers impact the quality of breast MR images, but not that of contrast-enhanced mammography (CEM), a study published February 5 in Surgical Oncology found.
Researchers led by Elisabeth van Haaren from the Zuyderland Medical Centre in Sittard-Geleen, the Netherlands, found that even after a low-dose injection (1 ml) of superparamagnetic iron oxide (SPIO) tracer, iron remnants stay behind in the breast tissue and disturb all MR images. However, they also observed no such effect on CEM images.
“CEM could be valuable alternative if additional imaging is needed in the follow-up of breast cancer,” van...
Source: AuntMinnie.com Headlines - February 6, 2024 Category: Radiology Authors: Amerigo Allegretto Tags: Clinical News Subspecialties MRI Ultrasound Breast Imaging Source Type: news
CEM image quality unaffected by iron particles from tracers
Low-dose iron oxide tracers impact the quality of breast MR images, but not that of contrast-enhanced mammography (CEM), a study published February 5 in Surgical Oncology found.
Researchers led by Elisabeth van Haaren from the Zuyderland Medical Centre in Sittard-Geleen, the Netherlands, found that even after a low-dose injection (1 ml) of superparamagnetic iron oxide (SPIO) tracer, iron remnants stay behind in the breast tissue and disturb all MR images. However, they also observed no such effect on CEM images.
“CEM could be valuable alternative if additional imaging is needed in the follow-up of breast cancer,” van...
Source: AuntMinnie.com Headlines - February 6, 2024 Category: Radiology Authors: Amerigo Allegretto Tags: Clinical News Subspecialties MRI Ultrasound Breast Imaging Source Type: news
Breast-conserving surgery is associated with a lower incidence of suicide among females with breast cancer in the United States: a population-based retrospective cohort study - Guo G, Li J, Zheng Y, Liu ZX, Lin H.
BACKGROUND: With comparable overall survival and local recurrence rates with mastectomy, breast-conserving surgery (BCS) has become the cornerstone of therapy for breast cancer; however, the difference in the incidence of suicide between BCS and mastectomy... (Source: SafetyLit)
Source: SafetyLit - January 15, 2024 Category: International Medicine & Public Health Tags: Research Methods, Surveillance and Codes, Models Source Type: news
Many Women Bypass Nearest Hospital for Breast Cancer Surgery
MONDAY, Jan. 8, 2024 -- Many women undergoing breast-conserving surgery (BCS) or mastectomy bypass their nearest hospitals, according to a study published online Jan. 8 in Cancer.
Ajay Aggarwal, M.D., Ph.D., from the London School of Hygiene and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 8, 2024 Category: Pharmaceuticals Source Type: news
Bilateral Mastectomy Not Tied to Better Survival in BRCA1-Positive Breast Cancer
(MedPage Today) -- SAN ANTONIO -- Bilateral mastectomy as initial treatment for women with breast cancer and a pathogenic BRCA1 variant was not linked to better survival, according to an international analysis.
Compared with breast-conserving... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 9, 2023 Category: Hematology Source Type: news
SABCS: Younger Postmenopausal Breast Cancer Patients Can Avoid Adjuvant RT
THURSDAY, Dec. 7, 2023 -- For postmenopausal women aged 50 to 69 years with stage 1 hormone receptor-positive breast cancer, the risk for recurrence is very low for those who do not undergo radiotherapy after breast-conserving surgery (BCS),... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 7, 2023 Category: Pharmaceuticals Source Type: news
Independent Scientific Paper by Doctors Using IceCure's ProSense(R) Published in Journal of Breast Imaging Presents Advantages of Cryoablation Breast Conserving Over Surgery in Early Breast Cancer Patients
Paper cites IceCure's ICE3 interim clinical study results as evidence of safety and efficacy of cryoablation in early-stage breast cancer
CAESAREA, Israel, Oct. 25, 2023 -- (Healthcare Sales & Marketing Network) -- IceCure Medical Ltd. (Nasdaq: ICCM) (... Devices, Oncology IceCure Medical, ProSense System, cryoablation (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 25, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth despite decline in demand for COVID-19 products
Basel, 19 October 2023Groupsales grow by 1%1at constant exchange rates (CER) in the first nine months, showing a strong increase of 7% in the third quarterExcluding COVID-19 products,Group salesincrease by 9%Pharmaceuticals Division sales grow by 9%, driven by continued high demand for newer medicinesDiagnostics Division ’s base businessincreases by 7%;overall divisional sales are down 18% due to a surge in demand for COVID-19 tests in 2022Highlightsin the third quarter of 2023:EU approval ofEvrysdifor babies under two months old with spinal muscular atrophyFirst approval of subcutaneous form of cancer immunotherapyTecen...
Source: Roche Media News - October 19, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth despite decline in demand for COVID-19 products
Groupsales grow by 1%1at constant exchange rates (CER) in the first nine months, showing a strong increase of 7% in the third quarterExcluding COVID-19 products,Group salesincrease by 9%Pharmaceuticals Division sales grow by 9%, driven by continued high demand for newer medicinesDiagnostics Division ’s base businessincreases by 7%;overall divisional sales are down 18% due to a surge in demand for COVID-19 tests in 2022Highlightsin the third quarter of 2023:EU approval ofEvrysdifor babies under two months old with spinal muscular atrophyFirst approval of subcutaneous form of cancer immunotherapyTecentriqPositive phase III...
Source: Roche Investor Update - October 19, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Tecentriq becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain, reducing treatment time to just minutes
Tecentriq subcutaneous (SC) is now approved in Great Britain for all indications of intravenousTecentriq, including certain types of lung, bladder, breast and liver cancer, offering a faster, more convenient option to receive treatmentAdministered under the skin within approx. seven minutes,Tecentriq SC saves time for patients and helps conserve resources in healthcare systems1Evaluations by the FDA, EMA and other health authorities globally are ongoingBasel, 29 August 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Tecentriq ® SC (atezolizumab) has been approved by the Medicines and Healthcare products Reg...
Source: Roche Investor Update - August 29, 2023 Category: Pharmaceuticals Source Type: news
